1
|
A new catalytic site functioning in antigen cleavage by H34 catalytic antibody light chain. Sci Rep 2022; 12:19185. [PMID: 36357546 PMCID: PMC9649737 DOI: 10.1038/s41598-022-23689-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Accepted: 11/03/2022] [Indexed: 11/12/2022] Open
Abstract
The cleavage reactions of catalytic antibodies are mediated by a serine protease mechanism involving a catalytic triad composed of His, Ser, and Asp residues, which reside in the variable region. Recently, we discovered a catalytic antibody, H34 wild type (H34wt), that is capable of enzymatically cleaving an immune-check point PD-1 peptide and recombinant PD-1; however, H34wt does not contain His residues in the variable region. To clarify the reason behind the catalytic features of H34wt and the amino acid residues involved in the catalytic reaction, we performed site-directed mutagenesis focusing on the amino acid residues involved in the cleavage reaction, followed by catalytic activity tests, immunological reactivity evaluation, and molecular modeling. The results revealed that the cleavage reaction by H34wt proceeds through the action of a new catalytic site composed of Arg, Thr, and Gln. This new scheme differs from that of the serine protease mechanism of catalytic antibodies.
Collapse
|
2
|
Navarro-Marchal SA, Griñán-Lisón C, Entrena JM, Ruiz-Alcalá G, Tristán-Manzano M, Martin F, Pérez-Victoria I, Peula-García JM, Marchal JA. Anti-CD44-Conjugated Olive Oil Liquid Nanocapsules for Targeting Pancreatic Cancer Stem Cells. Biomacromolecules 2021; 22:1374-1388. [PMID: 33724003 DOI: 10.1021/acs.biomac.0c01546] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
The latest trends in cancer research and nanomedicine focus on using nanocarriers to target cancer stem cells (CSCs). Specifically, lipid liquid nanocapsules are usually developed as nanocarriers for lipophilic drug delivery. Here, we developed olive oil liquid NCs (O2LNCs) functionalized by covalent coupling of an anti-CD44-fluorescein isothiocyanate antibody (αCD44). First, O2LNCs are formed by a core of olive oil surrounded by a shell containing phospholipids, a nonionic surfactant, and deoxycholic acid molecules. Then, O2LNCs were coated with an αCD44 antibody (αCD44-O2LNC). The optimization of an αCD44 coating procedure, a complete physicochemical characterization, as well as clear evidence of their efficacy in vitro and in vivo were demonstrated. Our results indicate the high targeted uptake of these αCD44-O2LNCs, and the increased antitumor efficacy (up to four times) of paclitaxel-loaded-αCD44-O2LNC compared to free paclitaxel in pancreatic CSCs (PCSCs). Also, αCD44-O2LNCs were able to selectively target PCSCs in an orthotopic xenotransplant in vivo model.
Collapse
Affiliation(s)
- Saúl A Navarro-Marchal
- Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, Granada 18100, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, 18071 Granada, Spain.,Excellence Research Unit "Modeling Nature" (MNat), University of Granada, 18071 Granada, Spain.,Department of Applied Physics, Faculty of Sciences, University of Granada, 18071 Granada, Spain
| | - Carmen Griñán-Lisón
- Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, Granada 18100, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, 18071 Granada, Spain.,Excellence Research Unit "Modeling Nature" (MNat), University of Granada, 18071 Granada, Spain
| | - José-Manuel Entrena
- Institute of Neuroscience, Biomedical Research Center, University of Granada, Parque Tecnológico de Ciencias de la Salud, Armilla, 18100 Granada, Spain.,Animal Behavior Research Unit, Scientific Instrumentation Center, University of Granada, Parque Tecnológico de Ciencias de la Salud, Armilla, 18100 Granada, Spain
| | - Gloria Ruiz-Alcalá
- Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, Granada 18100, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, 18071 Granada, Spain.,Excellence Research Unit "Modeling Nature" (MNat), University of Granada, 18071 Granada, Spain
| | - María Tristán-Manzano
- Genomic Medicine Department, GENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, Parque Tecnológico Ciencias de la Salud, Granada, Spain
| | - Francisco Martin
- Genomic Medicine Department, GENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, Parque Tecnológico Ciencias de la Salud, Granada, Spain
| | - Ignacio Pérez-Victoria
- Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Parque Tecnológico de Ciencias de la Salud, Avda. del Conocimiento 34, Armilla, 18016 Granada, Spain
| | - José Manuel Peula-García
- Biocolloids and Fluids Physics Group, Faculty of Sciences, University of Granada, 18014 Granada, Spain.,Department of Applied Physics II, University of Málaga, 29071 Málaga, Spain
| | - Juan Antonio Marchal
- Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM), University of Granada, Granada 18100, Spain.,Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, 18071 Granada, Spain.,Excellence Research Unit "Modeling Nature" (MNat), University of Granada, 18071 Granada, Spain.,Department of Human Anatomy and Embryology, Faculty of Medicine, University of Granada, 18016 Granada, Spain
| |
Collapse
|
3
|
Marculescu C, Lakshminarayanan A, Gault J, Knight JC, Folkes LK, Spink T, Robinson CV, Vallis K, Davis BG, Cornelissen B. Probing the limits of Q-tag bioconjugation of antibodies. Chem Commun (Camb) 2019; 55:11342-11345. [PMID: 31479092 PMCID: PMC6788405 DOI: 10.1039/c9cc02303h] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2019] [Accepted: 07/25/2019] [Indexed: 12/25/2022]
Abstract
Site-selective labelling of antibodies (Abs) can circumvent problems from heterogeneity of conventional conjugation. Here, we evaluate the industrially-applied chemoenzymatic 'Q-tag' strategy based on transglutaminase-mediated (TGase) amide-bond formation in the generation of 89Zr-radiolabelled antibody conjugates. We show that, despite previously suggested high regioselectivity of TGases, in the anti-Her2 Ab Herceptin™ more precise native MS indicates only 70-80% functionalization at the target site (Q298H), in competition with modification at other sites, such as Q3H critically close to the CDR1 region.
Collapse
Affiliation(s)
- Cristina Marculescu
- CRUK/MRC Oxford Institute for Radiation Oncology
, Department of Oncology, University of Oxford
,
Oxford
, OX3 7DQ
, UK
.
;
- Chemistry Research Laboratory
, University of Oxford
,
Oxford
, OX1 3TA
, UK
.
| | - Abirami Lakshminarayanan
- CRUK/MRC Oxford Institute for Radiation Oncology
, Department of Oncology, University of Oxford
,
Oxford
, OX3 7DQ
, UK
.
;
- Chemistry Research Laboratory
, University of Oxford
,
Oxford
, OX1 3TA
, UK
.
| | - Joseph Gault
- Chemistry Research Laboratory
, University of Oxford
,
Oxford
, OX1 3TA
, UK
.
| | - James C. Knight
- CRUK/MRC Oxford Institute for Radiation Oncology
, Department of Oncology, University of Oxford
,
Oxford
, OX3 7DQ
, UK
.
;
| | - Lisa K. Folkes
- CRUK/MRC Oxford Institute for Radiation Oncology
, Department of Oncology, University of Oxford
,
Oxford
, OX3 7DQ
, UK
.
;
| | - Thomas Spink
- CRUK/MRC Oxford Institute for Radiation Oncology
, Department of Oncology, University of Oxford
,
Oxford
, OX3 7DQ
, UK
.
;
| | - Carol V. Robinson
- Chemistry Research Laboratory
, University of Oxford
,
Oxford
, OX1 3TA
, UK
.
| | - Katherine Vallis
- CRUK/MRC Oxford Institute for Radiation Oncology
, Department of Oncology, University of Oxford
,
Oxford
, OX3 7DQ
, UK
.
;
| | - Benjamin G. Davis
- Chemistry Research Laboratory
, University of Oxford
,
Oxford
, OX1 3TA
, UK
.
| | - Bart Cornelissen
- CRUK/MRC Oxford Institute for Radiation Oncology
, Department of Oncology, University of Oxford
,
Oxford
, OX3 7DQ
, UK
.
;
| |
Collapse
|
4
|
Thran M, Mukherjee J, Pönisch M, Fiedler K, Thess A, Mui BL, Hope MJ, Tam YK, Horscroft N, Heidenreich R, Fotin-Mleczek M, Shoemaker CB, Schlake T. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med 2018; 9:1434-1447. [PMID: 28794134 PMCID: PMC5623855 DOI: 10.15252/emmm.201707678] [Citation(s) in RCA: 107] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
The delivery of genetic information has emerged as a valid therapeutic approach. Various reports have demonstrated that mRNA, besides its remarkable potential as vaccine, can also promote expression without inducing an adverse immune response against the encoded protein. In the current study, we set out to explore whether our technology based on chemically unmodified mRNA is suitable for passive immunization. To this end, various antibodies using different designs were expressed and characterized in vitro and in vivo in the fields of viral infections, toxin exposure, and cancer immunotherapies. Single injections of mRNA-lipid nanoparticle (LNP) were sufficient to establish rapid, strong, and long-lasting serum antibody titers in vivo, thereby enabling both prophylactic and therapeutic protection against lethal rabies infection or botulinum intoxication. Moreover, therapeutic mRNA-mediated antibody expression allowed mice to survive an otherwise lethal tumor challenge. In conclusion, the present study demonstrates the utility of formulated mRNA as a potent novel technology for passive immunization.
Collapse
Affiliation(s)
| | - Jean Mukherjee
- Department of Infectious Disease and Global Health, Tufts Cummings School of Veterinary Medicine, North Grafton, MA, USA
| | | | | | | | | | | | - Ying K Tam
- Acuitas Therapeutics, Vancouver, BC, Canada
| | | | | | | | - Charles B Shoemaker
- Department of Infectious Disease and Global Health, Tufts Cummings School of Veterinary Medicine, North Grafton, MA, USA
| | | |
Collapse
|
5
|
Carvalho AM, Manicardi A, Montes CV, Gunnoo SB, Schneider RJ, Madder A. Decoration of trastuzumab with short oligonucleotides: synthesis and detailed characterization. Org Biomol Chem 2018; 15:8923-8928. [PMID: 29038808 DOI: 10.1039/c7ob02216f] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Trastuzumab (Herceptin®) is an FDA-approved therapeutic antibody currently employed in the treatment of metastatic stages of breast cancer. Herein, we propose a simple, fast and cost-effective methodology to conjugate trastuzumab with 22-mer 5' thiol-modified oligonucleotides using a bifunctional crosslinker. The conjugates were successfully characterized by MALDI-ToF MS and SDS-PAGE, obviating the need for enzymatic digestion and difficult chromatographic separations. Furthermore, ELISA was performed to ensure that trastuzumab activity is not affected by oligonucleotide conjugation.
Collapse
Affiliation(s)
- A M Carvalho
- Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281 S4, 9000 Ghent, Belgium.
| | | | | | | | | | | |
Collapse
|
6
|
Mohamed HE, Mohamed AA, Al-Ghobashy MA, Fathalla FA, Abbas SS. Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol. J Pharm Biomed Anal 2018; 150:268-277. [DOI: 10.1016/j.jpba.2017.12.022] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2017] [Revised: 12/08/2017] [Accepted: 12/10/2017] [Indexed: 12/31/2022]
|
7
|
Suba D, Urbányi Z, Salgó A. Method development and qualification of capillary zone electrophoresis for investigation of therapeutic monoclonal antibody quality. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1032:224-229. [PMID: 27475867 DOI: 10.1016/j.jchromb.2016.07.026] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2016] [Revised: 07/04/2016] [Accepted: 07/14/2016] [Indexed: 12/31/2022]
Abstract
Capillary electrophoresis techniques are widely used in the analytical biotechnology. Different electrophoretic techniques are very adequate tools to monitor size-and charge heterogenities of protein drugs. Method descriptions and development studies of capillary zone electrophoresis (CZE) have been described in literature. Most of them are performed based on the classical one-factor-at-time (OFAT) approach. In this study a very simple method development approach is described for capillary zone electrophoresis: a "two-phase-four-step" approach is introduced which allows a rapid, iterative method development process and can be a good platform for CZE method. In every step the current analytical target profile and an appropriate control strategy were established to monitor the current stage of development. A very good platform was established to investigate intact and digested protein samples. Commercially available monoclonal antibody was chosen as model protein for the method development study. The CZE method was qualificated after the development process and the results were presented. The analytical system stability was represented by the calculated RSD% value of area percentage and migration time of the selected peaks (<0.8% and <5%) during the intermediate precision investigation.
Collapse
Affiliation(s)
- Dávid Suba
- Chemical Works of Gedeon Richter Plc, 1103 Budapest, Gyömrői út 19-21, Hungary, Hungary.
| | - Zoltán Urbányi
- Chemical Works of Gedeon Richter Plc, 1103 Budapest, Gyömrői út 19-21, Hungary, Hungary
| | - András Salgó
- Budapest University of Technology and Economics, 1111 Budapest, Műegyetem rakpart 3, Hungary
| |
Collapse
|
8
|
Hifumi E, Matsumoto S, Nakashima H, Itonaga S, Arakawa M, Katayama Y, Kato R, Uda T. A novel method of preparing the monoform structure of catalytic antibody light chain. FASEB J 2015; 30:895-908. [PMID: 26527062 DOI: 10.1096/fj.15-276394] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Accepted: 10/19/2015] [Indexed: 11/11/2022]
Abstract
Along with the development of antibody drugs and catalytic antibodies, the structural diversity (heterogeneity) of antibodies has been given attention. For >20 yr, detailed studies on the subject have not been conducted, because the phenomenon presents many difficult and complex problems. Structural diversity provides some (or many) isoforms of an antibody distinguished by different charges, different molecular sizes, and modifications of amino acid residues. For practical use, the antibody and the subunits must have a defined structure. In recent work, we have found that the copper (Cu) ion plays a substantial role in solving the diversity problem. In the current study, we used several catalytic antibody light chains to examine the effect of the Cu ion. In all cases, the different electrical charges of the molecule converged to a single charge, giving 1 peak in cation-exchange chromatography, as well as a single spot in 2-dimensional gel electrophoresis. The Cu-binding site was investigated by using mutagenesis, ultraviolet-visible spectroscopy, atomic force microscope analysis, and molecular modeling, which suggested that histidine and cysteine residues close to the C-terminus are involved with the binding site. The constant region domain of the antibody light chain played an important role in the heterogeneity of the light chain. Our findings may be a significant tool for preparing a single defined, not multiple, isoform structure.
Collapse
Affiliation(s)
- Emi Hifumi
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Shingo Matsumoto
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Hiroki Nakashima
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Shogo Itonaga
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Mitsue Arakawa
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Yoshiki Katayama
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Ryuichi Kato
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| | - Taizo Uda
- *Research Promotion Institute and Department of Applied Chemistry, Faculty of Engineering, Oita University, Oita, Japan; Nanotechnology Laboratory, Institute of Systems, Information Technologies, and Nanotechnologies (ISIT), Fukuoka, Japan; Graduate School of System Life Science, Kyushu University, Fukuoka, Japan; Tottori College of Nursing, Tottori, Japan; and High Energy Accelerator Research Organization, Tsukuba, Japan
| |
Collapse
|
9
|
Villacorta PJ, Salmerón-García A, Pelta DA, Cabeza J, Lario A, Navas N. Cluster-based comparison of the peptide mass fingerprint obtained by MALDI-TOF mass spectrometry. A case study: long-term stability of rituximab. Analyst 2015; 140:1717-30. [PMID: 25612326 DOI: 10.1039/c4an01806k] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We evaluated the use of the peptide mass fingerprint (PMF) obtained by matrix assisted laser desorption and ionization (MALDI) time-of-flight mass spectrometry (TOF-MS) to track changes in the structure of a protein. The first problem we had to overcome was the inherent complexity of the PMF, which makes it difficult to compare. We dealt with this problem by developing a cluster-based comparison algorithm which takes into account the proportional error made by the mass spectrometer. This procedure involves grouping together similar masses in an intelligent manner, so that we can determine which data correspond to the same peptide (any slight differences can be explained as experimental errors), and which of them are too different and thus more likely to represent different peptides. The proposed algorithm was applied to track changes in a commercially available monoclonal antibody (mAb), namely rituximab (RTX), prepared under the usual hospital conditions and stored refrigerated (4 °C) and frozen (-20 °C) for a long term study. PMFs were obtained periodically over three months. For each checked time, five replicates of the PMFs were obtained in order to evaluate the similarities between them by means of the occurrences of the particular peptides (m/z). After applying the algorithm to the PMF, different approaches were used to analyse the results. Surprisingly, all of them suggested that there were no differences between the two storage conditions tested, i.e. the RTX samples were almost equally well preserved when stored refrigerated at 4 °C or frozen at -20 °C. The cluster-based methodology is new in protein mass spectrometry and could be useful as an easy test for major changes in proteins and biopharmaceutics for diverse applications in industry and other fields, and could provide additional stability data in relation to the practical use of anticancer drugs.
Collapse
Affiliation(s)
- Pablo J Villacorta
- CITIC-UGR, Department of Computer Science and Artificial Intelligence, University of Granada, ETSIIT, C/Periodista Daniel Saucedo Aranda s/n, 18071 Granada, Spain
| | | | | | | | | | | |
Collapse
|
10
|
Murray D, Barnidge D. Characterization of immunoglobulin by mass spectrometry with applications for the clinical laboratory. Crit Rev Clin Lab Sci 2014; 50:91-102. [PMID: 24156651 DOI: 10.3109/10408363.2013.838206] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Studies monitoring immunoglobulin (Ig) antigen specificity have brought to light key Ig biomarkers for immunity, autoimmunity, cancer detection, and immune system function evaluation. A fundamentally new approach to the detection of Igs based on the primary structure of the Ig is beginning to emerge in the literature. This approach has only become feasible in light of advances in proteomics and rapid improvements in mass spectrometry (MS). Driven primarily by the development of Ig pharmaceuticals, Ig MS-based proteomic methods are revealing structural features which were previously unavailable with other characterization techniques. The task of adapting these techniques to clinical chemistry is in its infancy, but these methods have the potential to dramatically alter testing for Ig biomarkers. The purpose of this article is to review the advances that have been made in proteomic characterization of Igs by MS and the early attempts to apply these methods to clinical samples.
Collapse
Affiliation(s)
- David Murray
- Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN , USA
| | | |
Collapse
|
11
|
Nebija D, Noe CR, Urban E, Lachmann B. Quality control and stability studies with the monoclonal antibody, trastuzumab: application of 1D- vs. 2D-gel electrophoresis. Int J Mol Sci 2014; 15:6399-411. [PMID: 24739811 PMCID: PMC4013636 DOI: 10.3390/ijms15046399] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Revised: 03/10/2014] [Accepted: 03/31/2014] [Indexed: 12/05/2022] Open
Abstract
Recombinant monoclonal antibodies (rmAbs) are medicinal products obtained by rDNA technology. Consequently, like other biopharmaceuticals, they require the extensive and rigorous characterization of the quality attributes, such as identity, structural integrity, purity and stability. The aim of this work was to study the suitability of gel electrophoresis for the assessment of charge heterogeneity, post-translational modifications and the stability of the therapeutic, recombinant monoclonal antibody, trastuzumab. One-dimensional, SDS-PAGE, under reducing and non-reducing conditions, and two-dimensional gel electrophoresis were used for the determination of molecular mass (Mr), the isoelectric point (pI), charge-related isoform patterns and the stability of trastuzumab, subjected to stressed degradation and long-term conditions. For the assessment of the influence of glycosylation in the charge heterogeneity pattern of trastuzumab, an enzymatic deglycosylation study has been performed using N-glycosidase F and sialidase, whereas carboxypeptidase B was used for the lysine truncation study. Experimental data documented that 1D and 2D gel electrophoresis represent fast and easy methods to evaluate the quality of biological medicinal products. Important stability parameters, such as the protein aggregation, can be assessed, as well.
Collapse
Affiliation(s)
- Dashnor Nebija
- Department of Pharmaceutical Chemistry, Medical Faculty, Rr. Bulevardi i Deshmoreve, n.n. 10000 Pristina, Kosovo.
| | - Christian R Noe
- Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria.
| | - Ernst Urban
- Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria.
| | - Bodo Lachmann
- Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria.
| |
Collapse
|
12
|
|
13
|
Fekete S, Guillarme D. Possibilities of new generation columns packed with 1.3μm core–shell particles in gradient elution mode. J Chromatogr A 2013; 1320:86-95. [DOI: 10.1016/j.chroma.2013.10.061] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2013] [Revised: 09/23/2013] [Accepted: 10/18/2013] [Indexed: 11/24/2022]
|
14
|
Sánchez-Moreno P, Ortega-Vinuesa JL, Boulaiz H, Marchal JA, Peula-García JM. Synthesis and Characterization of Lipid Immuno-Nanocapsules for Directed Drug Delivery: Selective Antitumor Activity against HER2 Positive Breast-Cancer Cells. Biomacromolecules 2013; 14:4248-59. [DOI: 10.1021/bm401103t] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- Paola Sánchez-Moreno
- Biocolloid
and Fluid Physics Group, Department of Applied Physics, University of Granada, 18071 Granada, Spain
| | - Juan Luis Ortega-Vinuesa
- Biocolloid
and Fluid Physics Group, Department of Applied Physics, University of Granada, 18071 Granada, Spain
| | - Houría Boulaiz
- Human
Anatomy and Embryology Department, Regenerative Biomedicine Institute
(IBIMER), University of Granada, Campus de la Saluatd, 18071 Granada, Spain
| | - Juan Antonio Marchal
- Human
Anatomy and Embryology Department, Regenerative Biomedicine Institute
(IBIMER), University of Granada, Campus de la Saluatd, 18071 Granada, Spain
| | | |
Collapse
|
15
|
Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier-Cianférani S. Characterization of Therapeutic Antibodies and Related Products. Anal Chem 2012; 85:715-36. [DOI: 10.1021/ac3032355] [Citation(s) in RCA: 445] [Impact Index Per Article: 37.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Alain Beck
- Centre d’Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois,
France
| | - Elsa Wagner-Rousset
- Centre d’Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois,
France
| | - Daniel Ayoub
- Centre d’Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois,
France
| | - Alain Van Dorsselaer
- Laboratoire de Spectrométrie
de Masse BioOrganique (LSMBO), Université de Strasbourg, IPHC, 25 rue Becquerel 67087, Strasbourg, France and CNRS, UMR7178, 67037 Strasbourg, France
| | - Sarah Sanglier-Cianférani
- Laboratoire de Spectrométrie
de Masse BioOrganique (LSMBO), Université de Strasbourg, IPHC, 25 rue Becquerel 67087, Strasbourg, France and CNRS, UMR7178, 67037 Strasbourg, France
| |
Collapse
|